Grape King Bio Ltd (TPE:1707)

Taiwan · Delayed Price · Currency is TWD

82.50

-1.00 (-1.20%)

Oct 30, 2026, 1:30 PM CST

Market Cap	12.22B -33.7%
Revenue (ttm)	10.12B -6.9%
Net Income	1.15B -14.3%
EPS	7.69 -14.4%
Shares Out	148.14M
PE Ratio	10.73
Forward PE	12.63
Dividend	6.00 (7.27%)
Ex-Dividend Date	Jun 17, 2026

Volume	267,397
Open	83.50
Previous Close	83.50
Day's Range	82.30 - 83.70
52-Week Range	82.50 - 130.00
Beta	0.23
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulatio... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1969

Employees 501

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1707

Full Company Profile

Financial Performance

In 2025, Grape King Bio's revenue was 10.25 billion, a decrease of -8.14% compared to the previous year's 11.16 billion. Earnings were 1.22 billion, a decrease of -15.88%.

Financial Statements